These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6644533)

  • 41. Trimethadione tolerance test for the quantitative assessment of liver function in rats.
    Ishikawa A; Fukao K; Tanaka E; Tsuji K; Osada A; Yamamoto Y; Kiyosawa T; Iwasaki Y
    J Gastroenterol Hepatol; 1991; 6(4):363-7. PubMed ID: 1912445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simplified approach for determination of hepatic drug-oxidizing capacity using trimethadione metabolism as an indicator.
    Tanaka E; Kobayashi S; Nakamura K; Uchida E; Yasuhara H
    Biopharm Drug Dispos; 1989; 10(6):617-20. PubMed ID: 2611361
    [No Abstract]   [Full Text] [Related]  

  • 43. The effects of selective cytochrome P-450 inducing agents on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in rats.
    Tanaka E; Etoh H; Misawa S
    Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):375-8. PubMed ID: 2385760
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of the oxazolidinedione anticonvulsants trimethadione and dimethadione and the barbiturate homolog 5,5-dimethylbarbituric acid on N-nitrosodiethylamine-initiated renal and hepatic carcinogenesis in the F344/NCr rat.
    Diwan BA; Nims RW; Henneman JR; Ward JM; Lubet RA; Rice JM
    Arch Toxicol; 1992; 66(6):413-22. PubMed ID: 1444806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The metabolism and excretion of trimethadione in patients with percutaneous transhepatic biliary drainage and renal dysfunction.
    Tanaka E; Ishikawa A; Yamamoto Y; Fukao K; Iwasaki Y; Misawa S
    J Pharmacobiodyn; 1989 Mar; 12(3):145-8. PubMed ID: 2760794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.
    Abei M; Tanaka E; Tanaka N; Matsuzaki Y; Ikegami T; Ishikawa A; Osuga T
    J Gastroenterol; 1995 Aug; 30(4):478-84. PubMed ID: 7550858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog.
    Daling Z; Tanaka E; Nakamura T; Horie T
    Xenobiotica; 1994 Mar; 24(3):215-20. PubMed ID: 8009884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex-related differences in hepatic drug-oxidizing capacity of streptozotocin-induced diabetic rats.
    Tanaka E; Ishikawa A; Misawa S; Kuroiwa Y
    J Pharmacobiodyn; 1988 Jun; 11(6):416-23. PubMed ID: 3050023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strain differences of antipyrine, trimethadione, and debrisoquine metabolism in female rats.
    Tanaka E; Kobayashi S; Yasuhara H; Misawa S
    Res Commun Chem Pathol Pharmacol; 1990 Aug; 69(2):233-6. PubMed ID: 2396050
    [No Abstract]   [Full Text] [Related]  

  • 50. Trimethadione tolerance tests for the assessment of feasible size of hepatic resection in patients with hepatocellular carcinoma.
    Ishikawa A; Fukao K; Tsuji K; Osada A; Yamamoto Y; Ohtsuka M; Tanaka E
    J Gastroenterol Hepatol; 1993; 8(5):426-32. PubMed ID: 8218989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy.
    Uchida N; Kurata N; Shimada K; Nishimura Y; Yasuda K; Hashimoto M; Uchida E; Yasuhara H
    Jpn J Pharmacol; 1995 Aug; 68(4):431-9. PubMed ID: 8531418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatolithiasis and pancreatic carcinoma. Evaluation of pancreatic excretion test with 5,5-dimethyl-2,4-oxazolidinedione.
    Noda A; Kamiya N; Takayama T; Hayakawa T
    Arch Intern Med; 1977 Jun; 137(6):754-60. PubMed ID: 869646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pancreatic excretion of 5, 5-dimethyl-2, 4-oxazolidinedione in normal subjects.
    Noda A; Hayakawa T; Nakajima S; Suzuki T; Toda Y
    Am J Dig Dis; 1975 Nov; 20(11):1011-8. PubMed ID: 1199991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
    Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
    Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trimethadione: metabolism and assessment of hepatic drug-oxidizing capacity.
    Tanaka E; Funae Y
    Methods Enzymol; 1996; 272():163-9. PubMed ID: 8791774
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhibition of trimethadione and dimethadione teratogenicity by the cyclooxygenase inhibitor acetylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds.
    Wells PG; Nagai MK; Greco GS
    Toxicol Appl Pharmacol; 1989 Mar; 97(3):406-14. PubMed ID: 2609340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trimethadione metabolism as an index of hepatic drug-oxidizing capacity in dogs with liver ischemia.
    Tanaka E; Otsuka M; Yuzawa K; Isikawa A; Fukao K; Iwasaki Y
    Drug Metab Dispos; 1992; 20(5):773-4. PubMed ID: 1358585
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of the effects of trimethadione and its primary metabolite dimethadione on neuromuscular function and the effects of altered pH on the actions of dimethadione.
    Alderdice MT; McMillan JE
    J Pharmacol Exp Ther; 1982 Jun; 221(3):547-51. PubMed ID: 6283057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pancreatic excretion of 5,5-dimethyl-2,4-oxazolidinedione in patients with chronic pancreatitis.
    Noda A; Hayakawa T; Aoki I; Horiguchi Y; Toda Y
    Am J Dig Dis; 1975 Nov; 20(11):1019-26. PubMed ID: 1199992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.